SPRY · ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals’ Q1 2026 results reflect a deliberate inflection into commercial execution, with $17.5 million in U.S. neffy net product revenue representing the first full quarter of scaled commercialization following FDA approval. The $22.7 million total revenue includes $2.5 million in collaboration revenue recognized from ALK’s $5.0 million EU milestone — confirming successful regulatory execution in Europe — and $2.7 million in supply revenue, signaling early-stage partner monetization. However, the $60.6 million net loss underscores the intensity of upfront investment: SG&A surged to $72.2 million, primarily driven by direct-to-consumer marketing and the completion of sales force expansion to 148 representatives — a strategic move to deepen engagement with high-prescribing allergists. Management explicitly links this spend to long-term market share growth, citing increasing prescriber adoption (28,000+ HCPs, ~50% repeat) and structural advantages like the newly launched $199 point-of-sale program that reduces claim abandonment. While no formal financial guidance is issued, management reaffirms confidence in its cash position ($201.0 million as of March 31, 2026) funding operations through cash-flow break-even — a critical milestone given the absence of near-term profitability. Near-term catalysts include the anticipated CVS Caremark formulary decision in early June and the Q4 2026 interim readout from the Phase 2b CSU trial, which could validate expansion beyond anaphylaxis into chronic spontaneous urticaria — a $2B+ peak opportunity per the corporate presentation. Collectively, these disclosures signal transition from launch-phase execution to evidence-backed commercial scalability, with payor access and real-world adoption now central to valuation drivers.